CancerCore Biomedicine licenses Eisai oncology programs, raises fundsCore Biomedicine Inc. has completed a $21 million series A financing and been awarded a Japan Agency for Medical Research and Development (AMED) grant to advance its lead programs through discovery and early clinical development.